Literature DB >> 25887069

Hemostatic Factors, APOL1 Risk Variants, and the Risk of ESRD in the Atherosclerosis Risk in Communities Study.

Adrienne Tin1, Morgan E Grams2, Nisa M Maruthur3, Brad C Astor4, David Couper5, Thomas H Mosley6, Myriam Fornage7, Rulan S Parekh8, Josef Coresh9, Wen Hong Linda Kao9.   

Abstract

BACKGROUND AND OBJECTIVES: Hemostatic factors have been associated with kidney function decline, and evidence suggests stronger effects among African Americans. The presence of APOL1 renal risk variants, common in African Americans, might partly underlie this risk difference. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A total of 13,337 participants in the Atherosclerosis Risk in Communities study were followed from 1987-1989 until 2010. Participants were categorized into three groups by ancestry and APOL1 risk status: European Americans (n=10,206), African Americans with zero or one APOL1 risk allele (n=2,733), and African Americans with two APOL1 risk alleles (n=398). ESRD events were ascertained through linkage to the US Renal Data System. Cox regression was used to estimate the risk for ESRD associated with hemostatic factors (factor VIIc, factor VIIIc, fibrinogen, von Willebrand factor, protein C, and antithrombin III).
RESULTS: There were 232 cases of ESRD over 21.5 years (European Americans, 119; African Americans with zero or one APOL1 risk allele, 94; African Americans with two APOL1 risk alleles, 19). In unadjusted and adjusted analysis of the overall population, higher levels of all hemostatic factors, except antithrombin III, were significantly associated with ESRD (all P<0.05). Factor VIIc had the strongest association (per one interquartile range; adjusted hazard ratio, 1.46; 95% confidence interval, 1.21 to 1.76). With the exception of fibrinogen, the risk associated with each hemostatic factor was stronger in African Americans with two APOL1 risk alleles compared with the other two groups. Statistically significant interactions were seen for factor VIIIc and protein C (interaction between those with two APOL1 risk allele and the other two groups: P<0.02 for factor VIIIc and <0.04 for protein C).
CONCLUSIONS: Higher levels of factor VIIc, VIIIc, fibrinogen, von Willebrand factor, and protein C were associated with ESRD risk, with a significantly stronger association of factor VIIIc and protein C in African Americans with two APOL1 risk alleles.
Copyright © 2015 by the American Society of Nephrology.

Entities:  

Keywords:  end stage renal disease; genetic renal disease; human genetics; von Willebrand factor

Mesh:

Substances:

Year:  2015        PMID: 25887069      PMCID: PMC4422243          DOI: 10.2215/CJN.08340814

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  43 in total

1.  Population-based risk assessment of APOL1 on renal disease.

Authors:  David J Friedman; Julia Kozlitina; Giulio Genovese; Prachi Jog; Martin R Pollak
Journal:  J Am Soc Nephrol       Date:  2011-10-13       Impact factor: 10.121

2.  APOL1 variants associate with increased risk of CKD among African Americans.

Authors:  Meredith C Foster; Josef Coresh; Myriam Fornage; Brad C Astor; Morgan Grams; Nora Franceschini; Eric Boerwinkle; Rulan S Parekh; W H Linda Kao
Journal:  J Am Soc Nephrol       Date:  2013-06-13       Impact factor: 10.121

3.  APOL1 risk variants, race, and progression of chronic kidney disease.

Authors:  Afshin Parsa; W H Linda Kao; Dawei Xie; Brad C Astor; Man Li; Chi-yuan Hsu; Harold I Feldman; Rulan S Parekh; John W Kusek; Tom H Greene; Jeffrey C Fink; Amanda H Anderson; Michael J Choi; Jackson T Wright; James P Lash; Barry I Freedman; Akinlolu Ojo; Cheryl A Winkler; Dominic S Raj; Jeffrey B Kopp; Jiang He; Nancy G Jensvold; Kaixiang Tao; Michael S Lipkowitz; Lawrence J Appel
Journal:  N Engl J Med       Date:  2013-11-09       Impact factor: 91.245

4.  The innate immune factor apolipoprotein L1 restricts HIV-1 infection.

Authors:  Harry E Taylor; Atanu K Khatua; Waldemar Popik
Journal:  J Virol       Date:  2013-10-30       Impact factor: 5.103

5.  APOL1 variants and kidney disease in people of recent African ancestry.

Authors:  Giulio Genovese; David J Friedman; Martin R Pollak
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

6.  APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy.

Authors:  Jeffrey B Kopp; George W Nelson; Karmini Sampath; Randall C Johnson; Giulio Genovese; Ping An; David Friedman; William Briggs; Richard Dart; Stephen Korbet; Michele H Mokrzycki; Paul L Kimmel; Sophie Limou; Tejinder S Ahuja; Jeffrey S Berns; Justyna Fryc; Eric E Simon; Michael C Smith; Howard Trachtman; Donna M Michel; Jeffrey R Schelling; David Vlahov; Martin Pollak; Cheryl A Winkler
Journal:  J Am Soc Nephrol       Date:  2011-10-13       Impact factor: 10.121

7.  Evolution of the primate trypanolytic factor APOL1.

Authors:  Russell Thomson; Giulio Genovese; Chelsea Canon; Daniella Kovacsics; Matthew K Higgins; Mark Carrington; Cheryl A Winkler; Jeffrey Kopp; Charles Rotimi; Adebowale Adeyemo; Ayo Doumatey; George Ayodo; Seth L Alper; Martin R Pollak; David J Friedman; Jayne Raper
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-07       Impact factor: 11.205

8.  Plasma apolipoprotein L1 levels do not correlate with CKD.

Authors:  Leslie A Bruggeman; John F O'Toole; Michael D Ross; Sethu M Madhavan; Marlene Smurzynski; Kunling Wu; Ronald J Bosch; Samir Gupta; Martin R Pollak; John R Sedor; Robert C Kalayjian
Journal:  J Am Soc Nephrol       Date:  2013-11-14       Impact factor: 10.121

9.  APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability.

Authors:  Xiqian Lan; Aakash Jhaveri; Kang Cheng; Hongxiu Wen; Moin A Saleem; Peter W Mathieson; Joanna Mikulak; Sharon Aviram; Ashwani Malhotra; Karl Skorecki; Pravin C Singhal
Journal:  Am J Physiol Renal Physiol       Date:  2014-06-04

10.  Inflammation and coagulation markers and kidney function decline: the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Jade S Hiramoto; Ronit Katz; Carmen A Peralta; Joachim H Ix; Linda Fried; Mary Cushman; David Siscovick; Walter Palmas; Mark Sarnak; Michael G Shlipak
Journal:  Am J Kidney Dis       Date:  2012-05-04       Impact factor: 8.860

View more
  13 in total

1.  Apolipoprotein L1 Genetic Variants Are Associated with Chronic Kidney Disease but Not with Cardiovascular Disease in a Population Referred for Cardiac Catheterization.

Authors:  Hanghang Wang; Patrick H Pun; Lydia Kwee; Damian Craig; Carol Haynes; Megan Chryst-Ladd; Laura P Svetkey; Uptal D Patel; Elizabeth R Hauser; Martin R Pollak; William E Kraus; Svati H Shah
Journal:  Cardiorenal Med       Date:  2016-12-29       Impact factor: 2.041

2.  Hemostatic Factors, APOL1, and ESRD Risk: Another Piece of the Puzzle?

Authors:  Walter G Wasser; Etty Kruzel-Davila
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-17       Impact factor: 8.237

3.  Race, APOL1 Risk, and eGFR Decline in the General Population.

Authors:  Morgan E Grams; Casey M Rebholz; Yuan Chen; Andreea M Rawlings; Michelle M Estrella; Elizabeth Selvin; Lawrence J Appel; Adrienne Tin; Josef Coresh
Journal:  J Am Soc Nephrol       Date:  2016-03-10       Impact factor: 10.121

4.  Examination of Potential Modifiers of the Association of APOL1 Alleles with CKD Progression.

Authors:  Teresa K Chen; Michael J Choi; W H Linda Kao; Brad C Astor; Julia J Scialla; Lawrence J Appel; Liang Li; Michael S Lipkowitz; Myles Wolf; Rulan S Parekh; Cheryl A Winkler; Michelle M Estrella; Deidra C Crews
Journal:  Clin J Am Soc Nephrol       Date:  2015-10-01       Impact factor: 8.237

Review 5.  HDL in CKD-The Devil Is in the Detail.

Authors:  Florian Kronenberg
Journal:  J Am Soc Nephrol       Date:  2018-02-22       Impact factor: 10.121

6.  Patterns of Kidney Function Decline Associated with APOL1 Genotypes: Results from AASK.

Authors:  Adrienne Tin; Morgan E Grams; Michelle Estrella; Michael Lipkowitz; Tom H Greene; Wen Hong Linda Kao; Liang Li; Lawrence J Appel
Journal:  Clin J Am Soc Nephrol       Date:  2016-05-26       Impact factor: 8.237

7.  Mechanisms and mitigating factors for venous thromboembolism in chronic kidney disease: the REGARDS study.

Authors:  K L Cheung; N A Zakai; P W Callas; G Howard; B K Mahmoodi; C A Peralta; S E Judd; M Kurella Tamura; M Cushman
Journal:  J Thromb Haemost       Date:  2018-08-09       Impact factor: 5.824

Review 8.  Using Genetic Technologies To Reduce, Rather Than Widen, Health Disparities.

Authors:  Caren E Smith; Stephanie M Fullerton; Keith A Dookeran; Heather Hampel; Adrienne Tin; Nisa M Maruthur; Jonathan C Schisler; Jeffrey A Henderson; Katherine L Tucker; José M Ordovás
Journal:  Health Aff (Millwood)       Date:  2016-08-01       Impact factor: 6.301

Review 9.  Apolipoprotein L1 and Kidney Disease in African Americans.

Authors:  David J Friedman; Martin R Pollak
Journal:  Trends Endocrinol Metab       Date:  2016-03-03       Impact factor: 12.015

Review 10.  Genetics, Genomics, and Precision Medicine in End-Stage Kidney Disease.

Authors:  Jeffrey B Kopp; Cheryl A Winkler
Journal:  Semin Nephrol       Date:  2018-07       Impact factor: 5.299

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.